1 Therefore,
we developed (
1) a GSH-based photoaffinity probe (GSTABP
2 Here,
we developed 3D cell-line-based models of human syncytio
3 We develop a Bayesian semiparametric model, which combin
4 rumen fluke infection, it is imperative that
we develop a better understanding of the basic biology o
5 Here
we develop a biphasic hydrogel methodology, which along
6 Here,
we develop a chemical proteomics approach relying upon p
7 We develop a connectivity measure that successfully clas
8 Here,
we develop a convenient (17)O nuclear magnetic resonance
9 Here,
we develop a flexible architecture for computing damages
10 Hence,
we develop a flexible Bayesian variable selection model
11 Here,
we develop a framework for designing marine reserve netw
12 Finally,
we develop a GPC2-directed antibody-drug conjugate that
13 Here,
we develop a heterogeneous photonic integration platform
14 We develop a hierarchical pipeline, ThreaDomEx, for both
15 t samples collected within 4 y of the spill,
we develop a Macondo oil "fingerprint" and conservativel
16 We develop a mathematical model of the function of the 1
17 Building on research in social psychology,
we develop a mathematical model showing how conditioning
18 o explore the functional importance of 5hmU,
we develop a method for the genome-wide mapping of 5hmU-
19 Here
we develop a method to measure the electron and hole def
20 Here,
we develop a method to quantify errors in synthetic DNA
21 We develop a method to reconstruct, from measured displa
22 We develop a methodology to unveil the signals that are
23 Here
we develop a microprism-based cellular imaging approach
24 Next,
we develop a modeling framework that leverages transfer
25 on in soils are under increasing scrutiny as
we develop a more comprehensive understanding of global
26 Here,
we develop a more particularistic and mechanistic evolut
27 ly not achievable using traditional methods,
we develop a multi-sample-based method.
28 scenario-based life cycle assessment (LCA),
we develop a multiobjective optimization model to system
29 ural errors, diagnosed using error breeding,
we develop a new forecast approach that combines dynamic
30 Here
we develop a new method for total transcriptome profilin
31 Here,
we develop a new mouse model to transfer genes specifica
32 Here
we develop a novel Bayesian model to simultaneously esti
33 We develop a pore recognition approach to quantify simil
34 We develop a quantitative model that accounts for this e
35 Here
we develop a radiolabeled camelid single-domain antibody
36 In this paper,
we develop a random forest model incorporating aerosol o
37 Here,
we develop a robust bioinformatics pipeline exploiting H
38 Here,
we develop a screening strategy for modulators of ATP-PR
39 Here
we develop a simple and efficient crosstalk reduction ap
40 To capture this,
we develop a simple geometric measure, inness, that maps
41 In this work,
we develop a simple variational approach allowing one to
42 Finally,
we develop a statistical model that incorporates the unc
43 We develop a statistical model to predict June-July-Augu
44 We develop a statistical nondeterministic model, capable
45 Here,
we develop a statistical pipeline to assess statistical
46 Here,
we develop a statistically founded non-coding driver-det
47 Here
we develop a stochastic evolutionary model and show how
48 In this paper,
we develop a suite of methods, grounded in information t
49 Based on these observations,
we develop a summative model wherein the P-body assembly
50 f polyacrylamide gel electrophoresis (PAGE),
we develop a technique for fabrication of PAGE molecular
51 In this paper,
we develop a theoretical framework to investigate which
52 In this work,
we develop a theoretical model describing the physical m
53 We develop a theory of the ballistic-to-viscous crossove
54 We develop a transcriptional predictor of immunotherapy
55 We developed a 16-item model.
56 We developed a baboon model for IUGR studies using a mod
57 To gain insight into the TolA-pIII complex,
we developed a bacterial two-hybrid approach, named Oxi-
58 In this study,
we developed a biomimetic microfluidic tumor microenviro
59 Previously,
we developed a biophysically-based model of a binaural b
60 nce requirements within regulatory elements,
we developed a bisulfite-mediated nucleotide-conversion
61 First, in February 2016,
we developed a causality framework that defined question
62 We developed a cell delivery strategy based on a supramo
63 in the caudate, amygdala, and visual cortex,
we developed a classifier based on the dogs' subsequent
64 Thus,
we developed a clinically-relevant animal model for TON
65 To quantify the substructure of FAs,
we developed a clustering method based on expectation ma
66 In this study,
we developed a completely non-destructive strategy using
67 ases severity of retinopathy of prematurity,
we developed a composite rat model of UPI and oxygen-flu
68 equires multiple steps of data manipulation,
we developed a computational approach (bootstrapping) to
69 We developed a computational model of spinal circuits co
70 Here,
we developed a CRISPR-Cas9-based 'gene drive array' plat
71 First,
we developed a custom script that can detect intergenic
72 To address this problem,
we developed a data-driven approach to integrate and ana
73 To identify unknown vectors of Zika,
we developed a data-driven model linking vector species
74 We developed a derivation model to determine the relativ
75 Recently,
we developed a DNA walking system for the detection and
76 m the coordinated activity of multiple SCPs,
we developed a dynamic enrichment algorithm that flexibl
77 We developed a dynamic multimedia fate and transport mod
78 METHODS AND
We developed a dynamic transmission model of multi-strai
79 In this work,
we developed a field effect transistor (FET) biosensor u
80 We developed a filter-based feature selection method for
81 We developed a flexible Bayesian statistical approach to
82 For our workflow,
we developed a flexible tool for counting the number of
83 We developed a fluctuation test based on reversion to fl
84 We developed a genetic toolkit to study MT dynamics and
85 Here
we developed a genome-wide functional screen to interrog
86 We developed a Gibbs sampling Markov chain Monte Carlo a
87 mitations of existing computational methods,
we developed a global network random walk model for pred
88 atiotemporal control of mitotic progression,
we developed a high-content analysis (HCA) approach that
89 In this work,
we developed a high-density SNP array with 690,662 uniqu
90 N-chlorinated dipeptides in authentic water,
we developed a high-performance liquid chromatography-ta
91 To address this problem,
we developed a highly multiplexed single-cell DNA sequen
92 ribution of the TL to intrinsic termination,
we developed a kinetic assay that distinguishes effects
93 Furthermore,
we developed a kinome selective irreversible inhibitor 4
94 Here,
we developed a label-free technique to determine the spa
95 silon-GG epitope recognized during IAP, here
we developed a large-scale FASP method (LFASP) for diges
96 We developed a Markov-based microsimulation model, which
97 To investigate this,
we developed a mathematical model of the adrenal steroid
98 We developed a mathematical model that captures the beha
99 Additionally,
we developed a mathematical model, parameterized by cell
100 We developed a membrane-permeant, photoactivatable PI(4,
101 Here
we developed a Meso Scale Discovery (MSD)-based screenin
102 hydrostatic pressure-induced edema in vitro,
we developed a method of applied pressure to the basolat
103 We developed a method to directly capture lipid antigens
104 We developed a method to estimate glass transition tempe
105 As a step towards this goal,
we developed a method to examine whether individual gene
106 th as an indirect measure for shape readout,
we developed a methodology, DNAphi, for predicting EP in
107 Herein,
we developed a model of hematogenous infection in which
108 We developed a model to estimate GPP from the tower-base
109 In this article,
we developed a model-based clustering method and an R fu
110 Herein,
we developed a more sustainable method to produce silico
111 Here,
we developed a mouse model to study forelimb adaptation
112 chanisms mediating neuroblastoma metastasis,
we developed a mouse model using intracardiac injection
113 Moreover,
we developed a multiplex transcription activator-like ef
114 We developed a multiscale model of fibrinolysis that inc
115 To this end
we developed a nanoparticle (NP) platform, which is spec
116 To address this issue,
we developed a nanoparticle based platform, called nanoa
117 In this paper
we developed a new algorithm called ESPRIT-Forest for pa
118 In this study,
we developed a new analytical method that combines magne
119 We developed a new BMI that allows arbitrarily fast cont
120 atistical analysis of high-dimensional data,
we developed a new Debiased Sparse Partial Correlation a
121 We developed a new MALS methodology that has overcome th
122 We developed a new method (called REPPS) for incorporati
123 Here,
we developed a new method and an R package, to easily in
124 To solve such a problem,
we developed a new method called Optimistic Protein Asse
125 We developed a new method to quantify [K(+)] from T-wave
126 e of neutrophils in LPS-induced endotoxemia,
we developed a new mouse model, PMN(DTR) mice, in which
127 We developed a new multivariable linear model for GFR us
128 fectious-RNA incorporation into new virions,
we developed a new recombinant reovirus S1 gene that exp
129 We developed a new scoring system for calculating morbid
130 To address this,
we developed a new single-strand consensus sequencing as
131 In pursuit of these goals,
we developed a new synthetic approach that enables facil
132 Here,
we developed a novel alignment-free method, ChimeRScope
133 We developed a novel analytical framework for mapping an
134 Here,
we developed a novel and simple strategy to greatly enha
135 unanswered questions about these inhibitors,
we developed a novel approach to map the distribution of
136 We developed a novel approach towards the identification
137 To investigate this claim,
we developed a novel assay that allows for parallel prof
138 fects in mice generalize to another species,
we developed a novel Bace1(-/-) rat line using zinc-fing
139 We developed a novel hand-rearing paradigm in European s
140 To this end,
we developed a novel hydrosoluble zwitterionic MMP inhib
141 We developed a novel method to compute gene-level P-valu
142 We developed a novel methodology for burden estimation a
143 We developed a novel mirror box illusion to investigate
144 f the raft environment on prion propagation,
we developed a novel model for prion infection where cel
145 We developed a novel model of cancer-induced BTP using f
146 We developed a novel mouse strain in which the human low
147 Here,
we developed a novel receptor-ligand model of the adenos
148 We developed a novel score to predict posttransplant out
149 esentative of community exposure; therefore,
we developed a novel spatial phytosampling methodology t
150 We developed a panel of tunable expression platforms for
151 Using gamma-MSH as a template,
we developed a peptide, [Leu(3), Leu(7), Phe(8)]-gamma-M
152 We developed a platform for microfluidics-assisted cell
153 Here
we developed a population-level microsatellite profiling
154 For efficient synthetic access,
we developed a practical mixed solid- and solution-phase
155 To investigate their cellular dynamics,
we developed a quantitative assay, which detects differe
156 To address these questions,
we developed a quantitative polymerase chain reaction-ba
157 To enable rapid collection of such data,
we developed a relatively simple method using high-preci
158 In this work,
we developed a rice gene co-expression network for anthe
159 In conclusion,
we developed a robust ultrasound-based elastography meth
160 Here,
we developed a sensitive and accurate multiplex miRNA pr
161 Here,
we developed a sensitive sandwich enzyme-linked immunoso
162 To gain insights,
we developed a signature, "CA20", comprising centrosome
163 INTERPRETATION:
We developed a simple method that can be easily integrat
164 2016, 144, 204105),
we developed a simple method that resolves these issues.
165 We developed a simple model that explains both dissipati
166 Therefore,
we developed a simple quantitative framework to select a
167 We developed a single cell-based experimental system fro
168 Toward this goal,
we developed a software pipeline named digit that implem
169 We developed a statistical classification framework that
170 METHODS AND
We developed a stochastic compartmental model representi
171 s that explore pH and particle size effects,
we developed a stochastic simulation that exactly mimics
172 We developed a strategy for precise gene editing that do
173 To overcome these barriers,
we developed a strategy to macroencapsulate islets from
174 Previously
we developed a structure-based method for prediction of
175 To identify low KM chimeras
we developed a suitable bacterial selection system (E. c
176 Here
we developed a surface fluorination process to form a ho
177 To address these clinical shortcomings,
we developed a synthetic polycation, Universal Heparin R
178 To overcome this barrier,
we developed a synthetic-biology approach based on a tec
179 Using a high-throughput method,
we developed a T7 phage display cDNA library derived fro
180 atic environments (surface and groundwater),
we developed a technique for field continuous measuremen
181 Here,
we developed a technique for quantitative analysis using
182 d safety of engineered T-cell immunotherapy,
we developed a therapeutic transgene with 4 components:
183 CD39 in an in vivo cerebral ischemia model,
we developed a transgenic mouse expressing human CD39 (h
184 We developed a transmission-dynamic model on a dynamic n
185 We developed a two-alternative forced-choice task in an
186 wing ischemia are limited in their efficacy,
we developed a unique approach to protect the heart by t
187 We developed a WAFEX-guided principal analysis and unrav
188 Here,
we develop Act-seq, which minimizes artificially induced
189 Here
we develop AcTakines (Activity-on-Target cytokines), opt
190 To exploit this dual concept,
we developed agents exerting partial FXR agonism and sEH
191 We develop an algorithm named dpath that applies the con
192 Here,
we develop an algorithm to predict missing links based o
193 Here
we develop an alternative inhibitor for miRNAs, termed '
194 Here
we develop an analytical approach that corrects a major
195 Here
we develop an animal model utilizing direct ZIKV inocula
196 We develop an automated analysis pipeline to analyze and
197 Herein,
we develop an electrochemical sacrificial-template strat
198 As a byproduct,
we develop an order-parameter classification scheme that
199 nable precision analysis of R-loops in vivo,
we develop an RNase-H-based approach; this reveals predo
200 ate candidate selection for experimentation,
we developed an algorithm called GRACE (Gene Regulatory
201 Here,
we developed an algorithm, TransDetect, able to predict
202 Recently,
we developed an antibody-based PD-L1-targeted SPECT agen
203 We developed an approach to examine emergent behaviors t
204 al variants and their effects on phenotypes,
we developed an approach to mapping structural variants
205 In this work,
we developed an aptamer/graphene-based electrochemical b
206 We developed an assay for the high-throughput search for
207 Finally,
we developed an assay to assess whether neurons expressi
208 We developed an efficient cell culture system and isolat
209 less restricted mutual exclusivity analysis,
we developed an efficient method to estimate P -values w
210 We developed an electrophysiology-based classification o
211 We developed an evolutionary game theory model using Lot
212 To overcome this limitation,
we developed an ex vivo culture method of the mammary gl
213 Here,
we developed an immunotherapeutic regimen capable of eli
214 We developed an in silico model of two-dimensional actom
215 We developed an individual-based TB transmission model r
216 d previously implicated genes such as CDKN1A
We developed an innovative approach that integrates sing
217 In this regard,
we developed an innovative method for the inner-recyclin
218 Using an instrumental variable approach,
we developed an instrument for variations in local pollu
219 To investigate longitudinal responses,
we developed an intravital serial imaging approach that
220 To address this issue,
we developed an ITC empirical response model (ITC-ERM) t
221 Moreover,
we developed an oligonucleotide retrieval immunoprecipit
222 esponded with the hand being near an object,
we developed an online scaling feature in the BCI system
223 We developed an RNA-sequencing-based pipeline to discove
224 Here,
we develop and apply methods for cortex-wide Ca(2+) imag
225 AIM:
We developed and characterized a robust, consistent, and
226 Based on this dataset,
we developed and compared 2-class and 3-class DILI predi
227 Here,
we developed and comprehensively characterized a cellula
228 te the diagnosis of compromised individuals,
we developed and independently cross-validated a biomark
229 We developed and performed resistome analysis, an unbias
230 spending by individuals over many years, and
we developed and used an individual-level matching metho
231 We developed and validated a multivariate whole-blood mR
232 INTERPRETATION:
We developed and validated a novel clinical prediction m
233 We developed and validated a rapid, sensitive, and robus
234 roof of concept for anti-TRBC immunotherapy,
we developed anti-TRBC1 chimeric antigen receptor (CAR)
235 We developed approaches to management based on the study
236 Therefore,
we developed biodegradable polymeric microspheres for th
237 To investigate this question,
we developed breast cancer cell lines expressing an indu
238 BACKGROUND & AIMS:
We developed comprehensive models to determine risk of B
239 We developed core shell lipid-polymer hybrid nanoparticl
240 Here
we developed covariates for multiphenotype studies (CMS)
241 Based on these observations,
we developed cPPA programmable microcapsules whose paylo
242 By engineering C-terminal charges,
we develop CRY2high and CRY2low with elevated or suppres
243 We developed DC nanozymes with high enzymatic activity a
244 in next-generation sequencing (NGS) screens,
we developed DOMINO, a tool assessing the likelihood for
245 Here,
we develop flat and thin phase-conjugate nanostructures
246 We developed fMRI markers predicting moment-by-moment in
247 To improve our previous vaccine candidate,
we developed four new candidates that incorporate modifi
248 ess issues identified with existing methods,
we developed GB-eaSy, a GBS bioinformatics workflow that
249 We develop Genome-wide Reconstruction of Complex Structu
250 We developed inducible synthetic gene circuits that gene
251 We developed inoFISH to directly visualize and quantify
252 y miss these position-specific short motifs,
we developed kpLogo, a probability-based logo tool for i
253 bottleneck of modern untargeted lipidomics,
we developed LipidHunter, a new open source software for
254 We developed live-cell imaging assays which show that te
255 Here
we develop local self-uniformity (LSU) as a measure of a
256 Here
we develop mathematical models of Tfh cells in germinal
257 We developed mathematical models to study two different
258 Here
we develop methods for expression of fluorescent protein
259 ion accuracy to guide platform optimization,
we develop methods to standardize holograms for the purp
260 cies survive and persist outside their host,
we developed methods to more effectively culture C. auri
261 We developed molecular assays and portable optical imagi
262 We developed new genomic measures of damaging passenger
263 To suppress this survival mechanism,
we developed new thiourea quinazoline derivatives that a
264 and improved visualization of tumor margins,
we developed new viral-based platforms with 2 specific g
265 We developed novel genetically encoded ER-targeted low-a
266 Here
we developed novel replicating poxvirus NYVAC-based HIV/
267 We develop numerical simulations of Joule heating-enhanc
268 To address this issue
we developed OncoScore, a text-mining tool that ranks ge
269 We developed prediction models by means of an election d
270 The performance estimates
we develop provide important context to interpret clonal
271 Using this approach
we developed quantitative motifs for a selection of kina
272 To quantify how curvature forms,
we developed QuASAR (quantitative analysis of sacculus a
273 In the present work,
we developed regression between ovary development and th
274 We developed risk maps for autochthonous CHIKV transmiss
275 To better investigate this process,
we developed sensitive assays that use the fluorescein a
276 Here
we develop several mouse models in which hypothalamic st
277 Here,
we develop skin grafts from mouse and human epidermal pr
278 We developed SLICE, a novel algorithm that utilizes sing
279 We developed software that automatically analyzes the se
280 We developed statistical models relating seasonal temper
281 Here,
we develop such a method, termed APEX-RIP, which combine
282 Here
we develop surrogate Wnt agonists, water-soluble FZD-LRP
283 pical clinical reasons for switching agents,
we developed "
switching rules" at both 3 and 6 months af
284 sed in conjunction with a software tool that
we developed that converts an arbitrary pattern into DNA
285 In this review
we develop the argument that cholestatic liver diseases,
286 We develop the heterogeneous BLAST (H-BLAST), a fast par
287 To efficiently optimise the system,
we develop the Optometrist Algorithm, a stochastic pertu
288 and V3 regions and the gp120-gp41 interface,
we developed the CZA97 SOSIP.v4.2-M6.IT construct.
289 We developed the IsotopicLabelling R package, a tool abl
290 We developed the methodology for and investigated the ut
291 We developed the Molecular Biology of the Cell Ontology
292 Upon completion of follow-up studies,
we developed the working model that synaptic plasticity
293 Finally,
we developed this concept by performing the reductive al
294 larify the underlying regulatory mechanisms,
we developed three biologically anchored mathematical mo
295 Here,
we developed transgenic dy2J mice with muscle-specific e
296 We developed Triplex by constructing an rMVA encoding 3
297 In this work,
we develop two in vitro models to simulate the process o
298 Toward this goal,
we developed two mouse lines, including one harboring th
299 We developed urinary metabolite models for each diet and
300 We developed Yet Another RNA Normalization software pipe